Amphotropic pseudotyped retroviral vectors have typically been used to infect target cells
without prior concentration. Although this can yield high rates of infection, higher rates may …

During the production of clinical-grade retroviral vector supernatant, we noted significant
differences in the lactate production and glucose consumption of various producer cell lines …

We report increased transduction of human hematopoietic progenitor cells through a
combination of novel retroviral vector packaging cell lines, and improved vector supernatant …

Background Retroviruses are widely used to transfer genes to mammalian cells efficiently
and stably. However, genetic elements required for high-level gene expression are …

Most retroviral vectors used in preclinical and clinical studies contain a selectable marker
gene to facilitate the generation of producer clones. However, the expression of such genes …

Efficient human gene therapy will rely on efficient gene delivery systems. To date,
recombinant, engineered retroviruses are the most widely used vectors for stable clinical …

For many applications, human clinical therapies using retroviral vectors still require many
technological improvements in key areas of vector design and production. These …

Retroviral producer cells are generated by the introduction of a viral genome into" helper"
cell lines containing all the necessary components for viral packaging and the release of …

Background Because gene therapy of the future will primarily take an in vivo approach, a
number of problems associated with its current implementation exist. Currently, repeated …

We developed a new strategy that provides well-defined high-titer producer cells for
recombinant retroviruses in a minimum amount of time. The strategy involves the targeted …